Most people who've had their cholesterol checked think they know their cardiovascular risk. The standard panel shows Total Cholesterol, LDL-C, HDL-C, and Triglycerides. It's the test every physician orders, and it's been used for decades. The problem is, it's the wrong test.

Two better markers have existed for years. They're cheap, they're accurate, and they're endorsed by the European Society of Cardiology as Class I recommendations. And yet, most standard check-ups still don't include them. Here's what they are and why they matter.

Marker 1: ApoB

Atherosclerosis — the underlying cause of heart attacks and strokes — happens when cholesterol-carrying particles get stuck in the walls of your arteries. Every one of these particles has a single protein on its surface called Apolipoprotein B, or ApoB for short. One particle, one ApoB.

This means measuring ApoB tells you exactly how many atherogenic particles are in your bloodstream. It's a direct count.

LDL-C (traditional)

Measures the cholesterol content inside particles. Often calculated by estimation. Two people can have the same LDL-C but very different particle counts.

ApoB (better)

Directly counts every atherogenic particle. More accurate. More predictive. Recommended as Class I by the ESC.

Here's why this matters clinically. Two patients come in with an LDL-C of 120 mg/dL. Patient A has fewer, larger particles (each carrying more cholesterol). Patient B has many smaller particles (each carrying less). Their LDL-C is identical. Their risk is not — Patient B has far more particles that can lodge in arterial walls, and therefore much higher cardiovascular risk.

ApoB catches this. LDL-C misses it entirely.

Why isn't this in standard panels?

Inertia, mostly. The LDL-C estimate has been used since the 1970s. Changing standard-of-care takes decades. The ESC guidelines now recommend ApoB as the preferred marker — particularly for patients with metabolic syndrome, diabetes, or elevated triglycerides, where LDL-C is most unreliable.

Marker 2: Lipoprotein(a)

Lipoprotein(a) — usually written as Lp(a) — is a special type of LDL particle with an extra protein attached. Unlike regular LDL, your Lp(a) level is almost entirely determined by genetics. You cannot change it meaningfully with diet, exercise, or lifestyle.

And it's common. About 20% of the population — 1 in 5 people — has elevated Lp(a). High levels roughly double your lifetime risk of heart attack, stroke, and aortic valve disease.

The evidence is among the strongest in cardiology. Mendelian randomization studies — where researchers use genetic variants as natural experiments — have shown that Lp(a) is a direct causal driver of cardiovascular disease, not just an associated marker. It's not a correlation you can explain away.

"Lp(a) should be measured at least once in every adult's lifetime." — European Atherosclerosis Society Consensus Statement

Why does it matter if I can't change it?

Because while you can't lower Lp(a) directly, knowing you have it completely changes your treatment strategy for everything else. If your Lp(a) is high, your target LDL-C (or ApoB) needs to be much lower to achieve the same overall risk reduction. You move to aggressive statin therapy sooner. You monitor blood pressure more closely. Your cardiologist may recommend additional imaging.

In short: knowing your Lp(a) status isn't a diagnosis — it's a strategy change. And for the 20% of people who have elevated levels, it's the single most important piece of cardiovascular information they'll ever receive.

Pharmaceutical companies are also developing Lp(a)-lowering drugs that are expected to reach clinical use in the next few years. Patients who know their Lp(a) levels today will be first in line when those treatments arrive.

What this means for your check-up

Standard cardiovascular screening typically includes LDL-C, HDL-C, triglycerides, and total cholesterol. It usually does not include ApoB or Lp(a) — even though both are inexpensive, widely available, and have been recommended by international cardiology guidelines for years.

At Health Detectors, both are part of our core DETECT panel alongside triglycerides and HDL-C. Together, these four markers give a far more accurate picture of cardiovascular risk than the standard cholesterol panel ever could. And because Lp(a) is largely genetic, it only needs to be measured once — what you find stays with you for life.

The bottom line

If your last cardiovascular workup didn't include ApoB and Lp(a), it was incomplete. Both are cheap. Both are evidence-graded Class I. And both can change your treatment strategy in ways the traditional panel cannot.

References

  1. Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188.
  2. Burgess S, et al. Association of LPA variants with risk of coronary disease. JAMA Cardiol. 2018;3(7):619-627.
  3. Ference BA, et al. Association of genetic variants related to LPL and LDL receptor. JAMA. 2019;321(4):364-373.
  4. Kronenberg F, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease (EAS Consensus). Eur Heart J. 2022;43(39):3925-3946.
  5. Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287-1295.